Binod Dhakal, MD, provides a high-level overview of relapsed/refractory multiple myeloma (R/R MM), including the clinical hallmarks, risk factors, and patient stratification.
GPRC5D-Targeted Therapy Continues to be Effective After Dose Reduction in R/R Multiple Myeloma
At a live virtual event, Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma.
Read More
Advancing Myeloma Treatment With Blood-Based MRD Testing
In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Listen
Optimizing Cellular Therapy Programs for Community Practices
Rhonda Henschel, MBA, discussed the challenges and considerations for community oncology practices looking to implement cellular therapy programs.
FDA Calls for Boxed Warnings for CAR T-Cell Immunotherapies
Following an investigation that began in November 2023, the FDA now requires boxed warnings regarding T-cell malignancies on all BCMA- and CD19-directed T-cell products.
The Myeloma Trial Result I Did Not See Coming
A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.
FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.